To include your compound in the COVID-19 Resource Center, submit it here.

Actos pioglitazone: Postmarketing study data

In March, EMA's CHMP began a formal safety review of Actos to further explore a possible increased risk of bladder cancer

Read the full 217 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE